306 related articles for article (PubMed ID: 18489646)
21. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
23. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
[TBL] [Abstract][Full Text] [Related]
24. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.
Michaelson MD; Rosenthal DI; Smith MR
J Clin Oncol; 2004 Oct; 22(20):4233-4. PubMed ID: 15483039
[No Abstract] [Full Text] [Related]
25. Emerging strategies in bone health management for the adjuvant patient.
Coleman RE
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
[TBL] [Abstract][Full Text] [Related]
26. An update on a case of regression of lung metastases after radiotherapy for bone metastasis in renal cell carcinoma.
Jafri M; Protheroe A
Clin Oncol (R Coll Radiol); 2008 May; 20(4):316. PubMed ID: 18329259
[No Abstract] [Full Text] [Related]
27. [Evaluation of bone metastases from renal cell carcinoma].
Tsuda S; Koga S; Nishikido M; Tsurusaki T; Igawa T; Noguchi M; Kanda S; Matsuya F; Kanetake H
Hinyokika Kiyo; 2001 Mar; 47(3):155-8. PubMed ID: 11329954
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of bone metastases with bisphosphonates].
Gremaud M; Delouche D; Monnerat C
Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423
[TBL] [Abstract][Full Text] [Related]
30. [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Kise H; Kobayashi K; Arima K; Yanagawa M; Tochigi H; Kawamura J; Hioki T; Sugiura Y
Hinyokika Kiyo; 1996 Nov; 42(11):879-81. PubMed ID: 8973939
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of bisphosphonates: promising preclinical evidence.
Guise TA
Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines.
Pandha H; Birchall L; Meyer B; Wilson N; Relph K; Anderson C; Harrington K
J Urol; 2006 Nov; 176(5):2255-61. PubMed ID: 17070308
[TBL] [Abstract][Full Text] [Related]
33. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Tannir N; Jonasch E; Pagliaro LC; Mathew P; Siefker-Radtke A; Rhines L; Lin P; Tibbs R; Do KA; Lin SH; Tu SM
Cancer; 2006 Aug; 107(3):497-505. PubMed ID: 16795067
[TBL] [Abstract][Full Text] [Related]
34. Management of bisphosphonate treatment in clinical practice.
Aapro MS
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
[TBL] [Abstract][Full Text] [Related]
35. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
Phillips PM; Newman SA
Arch Ophthalmol; 2008 Jan; 126(1):137-9. PubMed ID: 18195236
[No Abstract] [Full Text] [Related]
36. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
37. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
38. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
39. [The application advances of bisphosphonates in bone metastasis].
Liang P
Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
[TBL] [Abstract][Full Text] [Related]
40. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Langer CJ
Clin Lung Cancer; 2005 Mar; 6(5):314-6. PubMed ID: 15845184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
